MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

NASDAQ:MRVI • US56600D1072

3.1 USD
+0.02 (+0.65%)
At close: Feb 20, 2026
3.1 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, MRVI scores 2 out of 10 in our fundamental rating. MRVI was compared to 58 industry peers in the Life Sciences Tools & Services industry. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability. MRVI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MRVI has reported negative net income.
  • MRVI had a negative operating cash flow in the past year.
  • In multiple years MRVI reported negative net income over the last 5 years.
  • MRVI had a positive operating cash flow in each of the past 5 years.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • MRVI's Return On Assets of -14.28% is in line compared to the rest of the industry. MRVI outperforms 41.38% of its industry peers.
  • MRVI has a worse Return On Equity (-49.40%) than 70.69% of its industry peers.
Industry RankSector Rank
ROA -14.28%
ROE -49.4%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • The Gross Margin of MRVI (20.86%) is worse than 82.76% of its industry peers.
  • MRVI's Gross Margin has declined in the last couple of years.
  • MRVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MRVI has been increased compared to 1 year ago.
  • MRVI has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRVI has been reduced compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • MRVI has an Altman-Z score of 0.95. This is a bad value and indicates that MRVI is not financially healthy and even has some risk of bankruptcy.
  • MRVI's Altman-Z score of 0.95 is in line compared to the rest of the industry. MRVI outperforms 48.28% of its industry peers.
  • MRVI has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
  • MRVI's Debt to Equity ratio of 1.29 is on the low side compared to the rest of the industry. MRVI is outperformed by 82.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACC12.16%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • MRVI has a Current Ratio of 5.29. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
  • MRVI has a Current ratio of 5.29. This is amongst the best in the industry. MRVI outperforms 82.76% of its industry peers.
  • A Quick Ratio of 4.56 indicates that MRVI has no problem at all paying its short term obligations.
  • MRVI has a better Quick ratio (4.56) than 82.76% of its industry peers.
Industry RankSector Rank
Current Ratio 5.29
Quick Ratio 4.56
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -900.00%.
  • MRVI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.56%.
  • Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 12.61% on average per year.
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%

3.2 Future

  • Based on estimates for the next years, MRVI will show a decrease in Earnings Per Share. The EPS will decrease by -8.88% on average per year.
  • MRVI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.39% yearly.
EPS Next Y-219.91%
EPS Next 2Y-46.67%
EPS Next 3Y-14.24%
EPS Next 5Y-8.88%
Revenue Next Year-28.9%
Revenue Next 2Y-11.56%
Revenue Next 3Y-5.56%
Revenue Next 5Y-0.39%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
  • Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • A cheap valuation may be justified as MRVI's earnings are expected to decrease with -14.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.67%
EPS Next 3Y-14.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (2/20/2026, 8:00:01 PM)

After market: 3.1 0 (0%)

3.1

+0.02 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners76.87%
Inst Owner Change-3.54%
Ins Owners5.54%
Ins Owner Change0.48%
Market Cap792.70M
Revenue(TTM)192.28M
Net Income(TTM)-121.24M
Analysts76.47
Price Target4.01 (29.35%)
Short Float %10.61%
Short Ratio9.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.34%
Min EPS beat(2)-10.61%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-15.88%
Min EPS beat(4)-47.06%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-14.07%
EPS beat(12)4
Avg EPS beat(12)-40.43%
EPS beat(16)8
Avg EPS beat(16)-26.46%
Revenue beat(2)0
Avg Revenue beat(2)-9.3%
Min Revenue beat(2)-16.71%
Max Revenue beat(2)-1.9%
Revenue beat(4)1
Avg Revenue beat(4)-4.39%
Min Revenue beat(4)-16.71%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.71%
Revenue beat(12)4
Avg Revenue beat(12)-2.4%
Revenue beat(16)7
Avg Revenue beat(16)-1.24%
PT rev (1m)0%
PT rev (3m)-1.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.77%
EPS NY rev (1m)0%
EPS NY rev (3m)0.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.12
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.75
BVpS0.96
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.28%
ROE -49.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.86%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.54%
Cap/Sales 9.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.29
Quick Ratio 4.56
Altman-Z 0.95
F-Score5
WACC12.16%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-219.91%
EPS Next 2Y-46.67%
EPS Next 3Y-14.24%
EPS Next 5Y-8.88%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%
Revenue Next Year-28.9%
Revenue Next 2Y-11.56%
Revenue Next 3Y-5.56%
Revenue Next 5Y-0.39%
EBIT growth 1Y-193.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2318.62%
EBIT Next 3Y108%
EBIT Next 5Y93.94%
FCF growth 1Y-141.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.7%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%

MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ

What is the ChartMill fundamental rating of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRVI.


What is the valuation status for MRVI stock?

ChartMill assigns a valuation rating of 0 / 10 to MARAVAI LIFESCIENCES HLDGS-A (MRVI). This can be considered as Overvalued.


Can you provide the profitability details for MARAVAI LIFESCIENCES HLDGS-A?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a profitability rating of 1 / 10.


What is the expected EPS growth for MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

The Earnings per Share (EPS) of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to decline by -219.91% in the next year.